A Clinical Trial Evaluating TG4050 in Head and Neck Cancer
← catalyst calendarNCT04183166 · readout in 498 d
Sponsored by Transgene (industry) · TNG.PA — their whole pipeline →.
Phase
Phase 1/2
Status
Active, not recruiting
Study type
Interventional
Design
Randomized · None · Treatment
Enrollment
80actual
Sites
14
Countries
France, Spain, United Kingdom +1
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2019-12-12 | actual | When the study began enrolling |
| Primary completion | 2027-12-30 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2031-12-30 | estimated | The whole study's end, after follow-up |
| First posted | 2019-12-03 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-01-16 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Squamous Cell Carcinoma of Head and Neck
Intervention
- Drug: TG4050
Primary outcomes
what the primary-completion date above is the date OFPhase I: Safety and tolerability (Adverse Event reported per CTCAE v5)
measured Up to 2 Years.
Phase I/II: Disease-Free Survival
measured Up to 2 years.
Permalink · TNG.PA's whole pipeline · Catalyst calendar · Every registered study · What changed